How can we interpret SARS-CoV-2 antibody test results?

Area of Science:

• Infectious Diseases
• Immunology
• Epidemiology

Background:

• The rapid spread of COVID-19 has spurred the development of numerous SARS-CoV-2 antibody tests.
• Many commercially available serological assays exhibit suboptimal sensitivity and specificity, lacking rigorous validation.
• Unresolved questions persist regarding the nuances of the humoral immune response to SARS-CoV-2.

Purpose of the Study:

• To highlight the critical need for proper validation of SARS-CoV-2 antibody tests.
• To address the frequent misinterpretation of serological data in COVID-19 diagnosis and epidemiology.
• To emphasize the importance of methodological rigor in serological research.

Main Methods:

• Review of current literature on SARS-CoV-2 serological assays.
• Analysis of the performance characteristics of commercial antibody tests.
• Discussion of the implications of serological data interpretation in various epidemiological contexts.

Main Results:

• A significant number of available antibody tests demonstrate inadequate performance.
• Misinterpretation of serological results is prevalent, particularly in regions with low disease prevalence.
• Methodological shortcomings are often overlooked in the pursuit of rapid research publication.

Conclusions:

• Serological assays are valuable tools for COVID-19 diagnosis and surveillance but require careful application.
• The interpretation of serological data must account for test performance and population prevalence.
• Prioritizing methodological rigor is essential for accurate understanding of the humoral response to SARS-CoV-2.